Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20794010 | 0.77 | RIPK1 (0.52) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL10041517 | 0.77 | RIPK1 (0.52) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL10533429 | 0.77 | RIPK1 (0.52) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL10041519 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14870536 | 0.72 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL1070651 | 0.72 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL11781437 | 0.72 | ALDH1A1 (0.44) | GAAMAOBALDH1A1KMT2ARAB9A | |
| SCHEMBL30991573 | 0.70 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL11973066 | 0.70 | ATM (0.44) | GAAALDH1A1KMT2AATMLMNA | |
| SCHEMBL11983050 | 0.70 | KDM1A (0.34) | GAACHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030909-A4 | IMMUNE ACTIVATION BY DOUBLE-STRANDED POLYNUCLEOTIDES | SENTRON MEDICAL INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050036993-A1 | Immune activation by double-stranded polynucleotides | KOHN LEONARD D (US) | 2005-02-17 | — | — | US | disclosed |
| US-20020142974-A1 | IMMUNE ACTIVATION BY DOUBLE-STRANDED POLYNUCLEOTIDES | SENTRON MEDICAL, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6365616-B1 | TRANSPLANT REJECTION | SENTRON MEDICAL, INC. | 2002-04-02 | — | — | US | disclosed |
| EP-1112072-A2 | METHIMAZOLE DERIVATIVES AND TAUTOMERIC CYCLIC THIONES TO TREAT AUTOIMMUNE DISEASES | Sentron Medical, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015768-A9 | IMMUNE ACTIVATION BY DOUBLE-STRANDED POLYNUCLEOTIDES | KOHN LEONARD D (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1030909-A1 | IMMUNE ACTIVATION BY DOUBLE-STRANDED POLYNUCLEOTIDES | KOHN, Leonard D. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000015768-A1 | IMMUNE ACTIVATION BY DOUBLE-STRANDED POLYNUCLEOTIDES | KOHN LEONARD D (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000012175-A2 | METHIMAZOLE DERIVATIVES AND TAUTOMERIC CYCLIC THIONES TO TREAT AUTOIMMUNE DISEASES | SENTRON MEDICAL, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050036993-A1 | Immune activation by double-stranded polynucleotides | MICA, CD74, HLA-DRB1 | GAA 1618/4885CHRNB2 899/4885CHRNB4 993/4885 |
| US-20020142974-A1 | IMMUNE ACTIVATION BY DOUBLE-STRANDED POLYNUCLEOTIDES | MICA, CD74, HLA-DRB1 | GAA 1618/4885CHRNB2 899/4885CHRNB4 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.